MacroGenics-Logo-(transparent-background).png
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 17:50 ET | MacroGenics, Inc.
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
November 02, 2022 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
inmunebio.jpg
INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference
September 07, 2022 09:00 ET | INmune Bio, Inc.
Boca Raton, FL, Sept. 07, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
September 02, 2022 07:00 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
July 25, 2022 16:01 ET | MacroGenics, Inc.
ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
July 08, 2022 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, July 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
June 08, 2022 16:01 ET | MacroGenics, Inc.
ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Appointment of William Heiden to Board of Directors
May 23, 2022 16:01 ET | MacroGenics, Inc.
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
May 17, 2022 16:01 ET | MacroGenics, Inc.
ROCKVILLE, MD, May 17, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
March 03, 2022 16:01 ET | MacroGenics, Inc.
ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...